ACLARIS THERAPEUTICS INC (ACRS) Stock Price, Quote, News and Overview
NASDAQ:ACRS - Nasdaq - US00461U1051 - Common Stock - Currency: USD
ACRS Quote, Performance and Key Statistics
1.96
-0.03 (-1.51%)
The current stock price of ACRS is 1.96 USD. In the past month the price decreased by -20.97%. In the past year, price increased by 39.01%.
ACRS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.52 | 882.60B | ||
| JNJ | JOHNSON & JOHNSON | 16.74 | 402.75B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.02 | 396.72B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.02 | 236.00B | ||
| MRK | MERCK & CO. INC. | 12.19 | 235.64B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.93 | 218.48B | ||
| PFE | PFIZER INC | 8.44 | 148.76B | ||
| SNY | SANOFI-ADR | 14.17 | 141.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 52.52 | 121.43B | ||
| GSK | GSK PLC-SPON ADR | 8.09 | 77.44B | ||
| ZTS | ZOETIS INC | 28.81 | 76.94B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.73 | 47.05B |
Related stock screener links
About ACRS
Company Profile
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 91 full-time employees. The company went IPO on 2015-10-07. The firm has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The firm's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The firm's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Company Info
ACLARIS THERAPEUTICS INC
701 Lee Road, Suite 103
Wayne PENNSYLVANIA 19087 US
CEO: Neal Walker
Employees: 89
Company Website: https://www.aclaristx.com/
Investor Relations: https://www.aclaristx.com/#!investors/juser
Phone: 14843247933
ACLARIS THERAPEUTICS INC / ACRS FAQ
What is the stock price of ACLARIS THERAPEUTICS INC today?
The current stock price of ACRS is 1.96 USD. The price decreased by -1.51% in the last trading session.
What is the ticker symbol for ACLARIS THERAPEUTICS INC stock?
The exchange symbol of ACLARIS THERAPEUTICS INC is ACRS and it is listed on the Nasdaq exchange.
On which exchange is ACRS stock listed?
ACRS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACLARIS THERAPEUTICS INC stock?
13 analysts have analysed ACRS and the average price target is 10.2 USD. This implies a price increase of 420.41% is expected in the next year compared to the current price of 1.96. Check the ACLARIS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACLARIS THERAPEUTICS INC worth?
ACLARIS THERAPEUTICS INC (ACRS) has a market capitalization of 209.76M USD. This makes ACRS a Micro Cap stock.
How many employees does ACLARIS THERAPEUTICS INC have?
ACLARIS THERAPEUTICS INC (ACRS) currently has 89 employees.
What are the support and resistance levels for ACLARIS THERAPEUTICS INC (ACRS) stock?
ACLARIS THERAPEUTICS INC (ACRS) has a support level at 1.95 and a resistance level at 2.6. Check the full technical report for a detailed analysis of ACRS support and resistance levels.
Is ACLARIS THERAPEUTICS INC (ACRS) expected to grow?
The Revenue of ACLARIS THERAPEUTICS INC (ACRS) is expected to decline by -36.68% in the next year. Check the estimates tab for more information on the ACRS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ACLARIS THERAPEUTICS INC (ACRS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACRS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACRS, evaluating the profitability, health, valuation and growth aspects
- ACLARIS THERAPEUTICS INC (ACRS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACLARIS THERAPEUTICS INC (ACRS) Sales and EPS estimates to see what analysts future expectations are.
- ACLARIS THERAPEUTICS INC (ACRS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACLARIS THERAPEUTICS INC (ACRS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACLARIS THERAPEUTICS INC (ACRS) Stock Chart to make your own analysis
- ACLARIS THERAPEUTICS INC (ACRS) Latest news and press-releases to stay up to date.
Does ACLARIS THERAPEUTICS INC (ACRS) stock pay dividends?
ACRS does not pay a dividend.
When does ACLARIS THERAPEUTICS INC (ACRS) report earnings?
ACLARIS THERAPEUTICS INC (ACRS) will report earnings on 2025-05-05, before the market open.
What is the Price/Earnings (PE) ratio of ACLARIS THERAPEUTICS INC (ACRS)?
ACLARIS THERAPEUTICS INC (ACRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
What is the Short Interest ratio of ACLARIS THERAPEUTICS INC (ACRS) stock?
The outstanding short interest for ACLARIS THERAPEUTICS INC (ACRS) is 3.77% of its float. Check the ownership tab for more information on the ACRS short interest.
ACRS Technical Analysis
ACRS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ACRS. While ACRS seems to be doing ok healthwise, there are quite some concerns on its profitability.
ACRS Financial Highlights
Over the last trailing twelve months ACRS reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 68.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.29% | ||
| ROE | -28.43% | ||
| Debt/Equity | 0 |
ACRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ACRS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 40.4% and a revenue growth -36.68% for ACRS